Caribou Biosciences, Inc.
CRBU · Price history
Price at last available close
$0.46
−$0.77 (-62.54%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Caribou Biosciences, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma.
How they make money
Caribou Biosciences is a clinical-stage biopharmaceutical company that generates revenue primarily through research collaboration and license agreements. The company focuses on developing genome-edited allogeneic cell therapies for oncology, relying on milestone payments and potential future royalties from partners rather than commercial product sales.
Products & services
The company develops CRISPR-edited allogeneic CAR-T cell therapies, including lead candidates CB-010, CB-011, and CB-012, designed to treat various hematologic malignancies.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer types
- Biopharmaceutical companiesSource
Customer concentration
The company does not have commercial products and therefore does not have customers in the traditional sense; revenue is concentrated in a small number of collaboration partners.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are not disclosed.Source
Business relationships & partnerships
- AbbVie — A strategic collaboration and license agreement for the development of CAR-T cell therapies.Source
Competitors
Strengths
- Proprietary chRDNA genome-editing technologySource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 43.8% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
17
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
17
Poor
Financial Strength
35
Business Quality / Moat
13
Management
0
Growth Quality
0
Risk / Durability
37
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
21
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
28/100
Building Historical Record
Model Score 28/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CRBU
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving CRBU's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can CRBU fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does CRBU's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for CRBU to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CRBU's current valuation?
Essential Investment Snapshot
Wall Street Score
17
Opportunity Score
21
Market Cap
$49.4M
P/E Ratio
-1.2
EPS
$-1.08
52-Week High
$3.54
52-Week Low
$1.22
Beta
2.28
Analyst Target
$5.00
Shares Outstanding
93.4M
Total Revenue
$10.0M
Total Debt
$26.7M
Dividend
No current dividend
Liquidation Value / Share
$1.05
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on CRBU.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary chRDNA genome-editing technology.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers for clinical supply.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
17
Sep 17, 2026
Change
-0.1
points
Current Score
17
Oct 1, 2026
Category Changes
CRBU decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
14
Projected Change
-2.4 points
Preliminary comparable-period financial changes suggest decline of approximately 2.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.46
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $11.2M | $10.0M | $34.5M | ···· | ···· | ···· | ···· |
| Cost of Revenue | $23.1M | $3.6M | $3.9M | $3.5M | ···· | ···· | ···· | ···· |
| Gross Profit | -$13.0M | $7.5M | $6.1M | $31.0M | ···· | ···· | ···· | ···· |
| Research & Development | $85.8M | $109.4M | $130.2M | $112.1M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $33.7M | $37.9M | $46.5M | $38.5M | ···· | ···· | ···· | ···· |
| Operating Expenses | $96.5M | $143.7M | $172.7M | $147.0M | ···· | ···· | ···· | ···· |
| EBITDA | -$104.1M | -$145.0M | -$145.2M | -$98.4M | ···· | ···· | ···· | ···· |
| Operating Income | -$109.5M | -$136.2M | -$166.6M | -$116.1M | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Income Before Tax | -$104.0M | -$148.7M | -$149.1M | -$101.9M | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$550K | -$550K | -$9K | $193K | ···· | ···· | ···· | ···· |
| Net Income | -$103.4M | -$148.1M | -$149.1M | -$102.1M | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.08 | $-1.59 | $-1.65 | $-1.38 | ···· | ···· | ···· | ···· |
| Basic Shares | 101M | 93.39M | 90.32M | 73.81M | ···· | ···· | ···· | ···· |
| Diluted Shares | 101M | 93.39M | 90.32M | 73.81M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.24
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+3.1%
Cash Change
+3.9%
Margin Change
+408.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included cash levels, net income margin. Pressure indicators included revenue growth, EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 43.8%. EPS declined 58.6%. Cash increased 3.9%. Total debt increased 3.1%. Net income margin improved by 408.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
Rumor Mill · CRBU
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial